# Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE)

> **NCT02476006** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 998 (actual)

## Conditions studied

- Hypercholesterolemia

## Interventions

- **DRUG:** ALIROCUMAB SAR236553 (REGN727)
- **DRUG:** placebo (for injection training only)
- **DRUG:** ezetimibe
- **DRUG:** atorvastatin
- **DRUG:** rosuvastatin
- **DRUG:** simvastatin

## Key facts

- **NCT ID:** NCT02476006
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-23
- **Primary completion:** 2019-04-12
- **Final completion:** 2019-04-12
- **Target enrollment:** 998 (ACTUAL)
- **Last updated:** 2022-03-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02476006

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02476006, "Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02476006. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*